While the platform giants have spent the last quarter trading guidance updates and indication breadth, the most interesting interventional news this week came from specialist companies clearing pivotal-grade milestones. Adagio Medical reported six-month results from the FULCRUM-VT pivotal trial of its vCLAS cryoablation system on April 27, hitting strong endpoints in a ventricular tachycardia population that has resisted catheter ablation for years. Imricor began U.S. commercial sales of NorthStar, the first cardiac mapping system designed for MR-guided ablation, on April 23. BrioHealth received conditional FDA approval on April 24 to begin a pediatric IDE trial of its BrioVAD ventricular assist device. Abbott posted six-month FlexPulse data on its TactiFlex Duo dual-energy catheter at HRS 2026. Read together, the week shows what specialist interventional companies look like when their pivotal evidence and U.S. commercial readiness arrive at the same time.
Adagio Medical’s vCLAS Cryoablation Pivotal Cleared Six-Month VT Marks That No One Else Has
Adagio Medical announced positive six-month results from FULCRUM-VT, a prospective multicenter IDE pivotal trial of the vCLAS Cryoablation System for ventricular tachycardia, on April 27 at the Heart Rhythm Society 2026 late-breaking session. The 209-patient trial was conducted at 20 U.S. and Canadian sites in patients with structural heart disease, both ischemic and non-ischemic cardiomyopathy. According to the company release and Medical Device Network coverage, the device achieved 98% acute non-inducibility of targeted VTs, 84% freedom from ICD shocks, 59% freedom from VT recurrence, and a 2.4% major adverse event rate at six months. Mean ablation time was 54 minutes per patient. The trial was the first to show equivalent effectiveness across both ischemic and non-ischemic VT substrates, which the company is positioning as a regulatory and commercial differentiator.
The structural read for founders is that VT ablation has been a durable white space underneath the larger AFib market, and a pure-play specialist just produced pivotal-grade data inside that space while the platform companies kept their attention on dual-energy AFib catheters. Adagio is a small public company without the salesforce, market cap, or installed base of the EP incumbents. The pivotal-grade endpoint set, the subsetted ischemic and non-ischemic effectiveness, and the safety profile constitute exactly the package a focused specialist needs to convert pivotal data into reimbursement-grade evidence. The lesson for founders building in EP-adjacent or other underserved interventional spaces is that the platform companies will continue to optimize for indication breadth, and that creates persistent room for specialists who finish the evidence work on a single hard substrate.
Imricor Began U.S. Commercial Sales of NorthStar, the First MR-Guided EP Mapping System
Imricor Medical Systems began U.S. commercial sales of its NorthStar Mapping System on April 23, with the system showcased at HRS 2026 in Chicago. According to the company announcement, NorthStar is the first cardiac mapping and guidance system designed specifically to operate inside the MRI environment. The system gives physicians a real-time soft-tissue visualization of cardiac structure and tissue characteristics during interventional procedures, with no fluoroscopy required. Imricor reported that the U.S. commercial team is generating early demand and building a pipeline focused on early-adopter centers.
The implication for founders building in interventional imaging or hybrid procedural environments is that the MR-guided EP suite has finally cleared the regulatory and infrastructure thresholds that have stalled it for a decade. Imricor is a small-cap U.S.-listed company, and the U.S. commercial launch is a meaningful operational milestone after years of development and European-first deployment. Founders developing devices that depend on imaging or environmental innovation should read the NorthStar launch as a proof point that institutional demand for radiation-free EP procedures is now real enough to support a focused commercial ramp.
BrioHealth Received Conditional FDA Approval to Run a Pediatric VAD IDE Trial
BrioHealth Solutions announced on April 24 that it received conditional FDA approval to launch the Brio4Kids Trial, a pediatric clinical evaluation of the BrioVAD System under the existing INNOVATE IDE. According to the company press release, the trial will study the BrioVAD in pediatric patients with advanced heart failure, with enrollment expected to start in mid-2026 and initial data anticipated in Q4 2026. The BrioVAD device features a fully magnetically suspended pump and a thin driveline, designed to address gaps in pediatric heart failure treatment.
For founders building in advanced heart failure or other pediatric-indication device categories, BrioHealth’s conditional approval is a useful reference for how the FDA is handling parallel adult and pediatric IDE designs. Building the pediatric extension under the existing IDE rather than starting a separate program preserves capital and timeline. The structural lesson is that pediatric extensions can be designed into the original IDE strategy from the outset, rather than treated as a follow-on program once the adult device is commercially established.
Abbott’s TactiFlex Duo Posted Six-Month Dual-Energy AFib Data at HRS 2026
Abbott reported six-month results from its FlexPulse trial of the TactiFlex Duo dual-energy ablation catheter at HRS 2026, per MedTech Dive. The 188-patient study in intermittent atrial fibrillation reported 87% arrhythmia-free survival at six months and a 98.3% safety profile with no major safety events. The TactiFlex Duo combines pulsed field and radiofrequency energy in a single contact-force-sensing catheter, positioning Abbott as the third major EP company with a credible dual-energy portfolio entry behind Boston Scientific and Medtronic. The data lands in the same conference cycle where Boston Scientific reported its AVANT GUARD first-line PFA results in persistent AFib and Medtronic showed early Sphere-9 VT data.
The competitive read is that dual-energy is now table stakes for EP platform players, and the next round of differentiation will be on indication-specific evidence and reimbursement positioning rather than on energy modality alone. Founders building niche or specialist EP devices should treat dual-energy AFib as a settled platform story and plan their evidence and commercial strategy against substrates and indications where the dual-energy approach does not yet have differentiated data.
Dave’s take
The specialist pattern this week is the one I would push founders to study most carefully. The platform companies are running indication-breadth plays because that is what their cost structure requires. Adagio, Imricor, and BrioHealth are running focused-substrate plays because that is what their cost structure can sustain. If you are building a single-substrate or single-indication interventional device, your evidence work has to land at pivotal-grade depth on the substrate the platform companies have not yet contested, and your commercial readiness has to arrive at the same time. The companies that finish that combination capture the durable white space; the companies that finish only one half end up acquired into the platform play they were trying to differentiate from.
I’m here to help you scale.
Work With Dave